Hester Biosciences Ltd
NSE:HESTERBIO

Watchlist Manager
Hester Biosciences Ltd Logo
Hester Biosciences Ltd
NSE:HESTERBIO
Watchlist
Price: 2 408 INR 1.09% Market Closed
Market Cap: 20.5B INR
Have any thoughts about
Hester Biosciences Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one HESTERBIO stock under the Base Case scenario is 2 445.8 INR. Compared to the current market price of 2 408 INR, Hester Biosciences Ltd is Undervalued by 2%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HESTERBIO Relative Value
Base Case
2 445.8 INR
Undervaluation 2%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

6.6
P/S
P/S
Price to Sales
6.6
vs History
52
vs Industry
54
Median 3Y
6.5
Median 5Y
7
Industry
7.6
Forward
6
More Details
87.3
P/E
P/E
Price to Earnings
87.3
vs History
4
vs Industry
1
Median 3Y
57.9
Median 5Y
52.7
Industry
22.1
Forward
39.9
More Details
30.8
P/OCF
P/OCF
Price to OCF
30.8
vs History
71
vs Industry
4
Median 3Y
59.1
Median 5Y
43.5
Industry
21.9
More Details
381.7
P/FCFE
P/FCFE
Price to FCFE
381.7
vs History
9
vs Industry
Median 3Y
-60.2
Median 5Y
-77.8
Industry
23.4
More Details
6.8
P/B
P/B
Price to Book Value
6.8
vs History
38
vs Industry
11
Median 3Y
6.3
Median 5Y
6.8
Industry
2.5
More Details
6.9
EV/S
EV/S
Enterprise Value to Sales
6.9
vs History
53
vs Industry
44
Median 3Y
6.9
Median 5Y
7.4
Industry
7.5
Forward
6.3
More Details
9.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
9.8
vs History
34
vs Industry
35
Median 3Y
9.9
Median 5Y
9.7
Industry
9.3
More Details
34.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
34.4
vs History
19
vs Industry
2
Median 3Y
33.9
Median 5Y
28.6
Industry
4.2
Forward
25.4
More Details
46
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
46
vs History
30
vs Industry
1
Median 3Y
48.7
Median 5Y
41.9
Industry
4
More Details
32.5
EV/OCF
EV/OCF
Enterprise Value to OCF
32.5
vs History
71
vs Industry
3
Median 3Y
64.2
Median 5Y
46.7
Industry
5.9
More Details
50.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
50.2
vs History
28
vs Industry
2
Median 3Y
-13.1
Median 5Y
-24.1
Industry
3.9
More Details
3.6
EV/IC
EV/IC
Enterprise Value to IC
3.6
vs History
50
vs Industry
35
Median 3Y
3.2
Median 5Y
3.8
Industry
4.5
More Details

Multiples Across Competitors

HESTERBIO Competitors Multiples
Hester Biosciences Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Hester Biosciences Ltd
NSE:HESTERBIO
20.5B INR 6.6 87.3 34.4 46
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 142 781.8 -181 287 -220 140.1 -217 628.1
US
Abbvie Inc
NYSE:ABBV
315.2B USD 5.7 62 15.4 23.7
US
Amgen Inc
NASDAQ:AMGN
141.9B USD 4.4 33.5 16.1 30.4
US
Gilead Sciences Inc
NASDAQ:GILD
116.4B USD 4.1 923.6 10.3 10.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.5B USD 9.8 -217.7 21.5 22.6
US
Epizyme Inc
F:EPE
94.1B EUR 1 847 -471.3 -513.3 -499.6
AU
CSL Ltd
ASX:CSL
135.7B AUD 5.7 32.1 19.9 24.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD 5.7 16.9 15.4 17.1
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.6 -52.9
NL
argenx SE
XBRU:ARGX
36B EUR 19 -133.7 -109.3 -79.6
P/S Multiple
Revenue Growth P/S to Growth
IN
Hester Biosciences Ltd
NSE:HESTERBIO
Average P/S: 3 467 700.7
6.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
38 142 781.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.4
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
34%
0.3
US
E
Epizyme Inc
F:EPE
1 847
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
23%
0.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19
220%
0.1
P/E Multiple
Earnings Growth P/E to Growth
IN
Hester Biosciences Ltd
NSE:HESTERBIO
Average P/E: 192.6
87.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 287 N/A N/A
US
Abbvie Inc
NYSE:ABBV
62
413%
0.2
US
Amgen Inc
NASDAQ:AMGN
33.5
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
923.6
77%
12
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -217.7
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -471.3 N/A N/A
AU
CSL Ltd
ASX:CSL
32.1
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -133.7 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Hester Biosciences Ltd
NSE:HESTERBIO
Average EV/EBITDA: 19
34.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -220 140.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16.1
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.5
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -513.3 N/A N/A
AU
CSL Ltd
ASX:CSL
19.9
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.4
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -109.3 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Hester Biosciences Ltd
NSE:HESTERBIO
Average EV/EBIT: 25
46
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 628.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.4
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.6
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -499.6 N/A N/A
AU
CSL Ltd
ASX:CSL
24.8
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.6 N/A N/A

See Also

Summary
HESTERBIO intrinsic value, competitors valuation, and company profile.
DCF Valuation
HESTERBIO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
HESTERBIO stock valuation using valuation multiples.
Wall Street Estimates
HESTERBIO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
HESTERBIO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.